Landos Biopharma, Inc.
Pharmaceutical ManufacturingVirginia, United States11-50 Employees
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, focused on developing first-in-class therapeutics for autoimmune diseases. The organization aims to fill gaps in current treatment options by pursuing safer and more effective approaches, supported by a small-to-mid-sized team advancing its clinical programs. The company operates within the pharmaceutical sector and concentrates on translating its scientific initiatives into therapeutic candidates for immune-mediated conditions. Landos’ lead program, NX-13, is under mid-stage evaluation in ulcerative colitis, highlighting its focus on inflammatory bowel diseases as a target. It has pursued research collaborations to further characterize NX-13, including a strategic partnership with KU Leuven announced in 2023. In March 2024, Landos disclosed a merger agreement with Bespin Subsidiary, LLC and its parent AbbVie, with the intention that Landos would become a wholly owned subsidiary as part of the transaction.
1-888-653-2347 
support@leadiq.com 
